CN114728053A - 抗肠道疾病的免疫原性组合物和用于制备其的方法 - Google Patents

抗肠道疾病的免疫原性组合物和用于制备其的方法 Download PDF

Info

Publication number
CN114728053A
CN114728053A CN202080074655.7A CN202080074655A CN114728053A CN 114728053 A CN114728053 A CN 114728053A CN 202080074655 A CN202080074655 A CN 202080074655A CN 114728053 A CN114728053 A CN 114728053A
Authority
CN
China
Prior art keywords
polysorbate
antigen
salmonella
saccharide
carrier protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080074655.7A
Other languages
English (en)
Chinese (zh)
Inventor
拉耶夫·姆哈尔萨坎特·德雷
桑巴哈吉·尚卡尔·皮萨尔
达塔特列娅·萨尔马·安纳姆拉朱
尼基·达塔特拉亚·阿瓦拉斯卡尔
约格什·图卡拉姆·洪德卡里
安尼尔·皮拉伊劳·塔克利卡尔
苏尼·库马尔·戈尔
钱德拉谢卡尔·德瓦尔卡纳特·卡马特
维什哈尔·巴拉特·恰范
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serum Institute of India Pvt Ltd
Original Assignee
Serum Institute of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute of India Pvt Ltd filed Critical Serum Institute of India Pvt Ltd
Publication of CN114728053A publication Critical patent/CN114728053A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080074655.7A 2019-09-03 2020-09-02 抗肠道疾病的免疫原性组合物和用于制备其的方法 Pending CN114728053A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921035435 2019-09-03
IN201921035435 2019-09-03
PCT/IN2020/050763 WO2021044436A2 (en) 2019-09-03 2020-09-02 Immunogenic compositions against enteric diseases and methods for its preparation thereof

Publications (1)

Publication Number Publication Date
CN114728053A true CN114728053A (zh) 2022-07-08

Family

ID=72659843

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080074655.7A Pending CN114728053A (zh) 2019-09-03 2020-09-02 抗肠道疾病的免疫原性组合物和用于制备其的方法

Country Status (23)

Country Link
US (2) US20230149524A1 (https=)
EP (2) EP4249061A3 (https=)
JP (2) JP7732974B2 (https=)
KR (2) KR20240155975A (https=)
CN (1) CN114728053A (https=)
AR (1) AR119884A1 (https=)
AU (1) AU2020343943A1 (https=)
BR (1) BR112022003892A2 (https=)
CA (1) CA3149972A1 (https=)
CO (1) CO2022003789A2 (https=)
CR (1) CR20220132A (https=)
EC (1) ECSP22031077A (https=)
GB (2) GB2603362B (https=)
GE (2) GEP20257808B (https=)
IL (1) IL291006B2 (https=)
JO (1) JOP20200214A1 (https=)
MA (1) MA56283A1 (https=)
MX (1) MX2022002693A (https=)
PE (1) PE20221442A1 (https=)
PH (1) PH12022550525A1 (https=)
PY (1) PY2051122A (https=)
WO (1) WO2021044436A2 (https=)
ZA (1) ZA202203368B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121569027A (zh) * 2023-07-21 2026-02-24 葛兰素史克生物有限公司 免疫原性组合物
WO2025217253A1 (en) * 2024-04-12 2025-10-16 Neogen Corporation Neutralizing compositions and related methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102935226A (zh) * 2012-11-16 2013-02-20 罗益（无锡）生物制药有限公司 伤寒甲型副伤寒结合疫苗及其制备方法
CN104383532A (zh) * 2014-12-02 2015-03-04 云南沃森生物技术股份有限公司 一种用乙肝表面抗原为载体蛋白的细菌多糖蛋白结合物疫苗及其制备方法
CN105744951A (zh) * 2013-08-24 2016-07-06 巴拉特生物技术国际有限公司 细菌疫苗及其制备方法
US20180185465A1 (en) * 2015-07-04 2018-07-05 Bharat Biotech International Limited Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides
US20190134177A1 (en) * 2016-04-25 2019-05-09 National Institute Of Immunology Conjugate for vaccination against typhoid comprising chemical conjugate of vi polysaccharide and flagellin, a process for producing the same and a composition comprising the conjugate

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
AU1420897A (en) * 1996-12-18 1998-07-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Conjugate vaccine for (salmonella paratyphi) a
DE69941574D1 (de) 1998-08-19 2009-12-03 Baxter Healthcare Sa Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
PE20110072A1 (es) 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
GB0700135D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Vaccine
FR2938265B1 (fr) 2008-11-12 2011-07-15 Univ Claude Bernard Lyon Procede pour le pilotage d'un traitement de depolymerisation par ultrasons d'un biopolymere hydrosoluble
CA2836153C (en) * 2009-12-17 2016-06-21 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
US9011871B2 (en) * 2011-11-07 2015-04-21 University Of Maryland, Baltimore Broad spectrum vaccine against typhoidal and non-typhoidal Salmonella disease
IN2012MU00206A (https=) * 2012-01-20 2013-08-09
MX354103B (es) 2012-01-30 2018-02-13 Serum Inst India Ltd Composicion inmunogenica.
CN104587461A (zh) * 2015-01-05 2015-05-06 云南沃森生物技术股份有限公司 伤寒、甲型乙型副伤寒多糖蛋白结合型多价联合疫苗
MY191163A (en) 2016-08-26 2022-06-03 The Centers For Disease Control And Prevention Cdc Multivalent vaccine composition
US11739356B2 (en) * 2017-05-05 2023-08-29 Serum Institute Of India Private Limited Method for removal of impurities from bacterial capsular polysaccharide based preparations
CN111032078A (zh) 2017-07-18 2020-04-17 血清研究所印度私人有限公司 具有改善的稳定性、增强的免疫原性和降低的反应原性的免疫原性组合物及其制备方法
EA202190778A1 (ru) 2018-10-12 2021-08-05 Серум Инститьют Оф Индия Прайват Лтд Композиция комбинированной вакцины, содержащая уменьшенную дозу инактивированного полиовируса, и способ её получения
MX2021005500A (es) * 2018-11-10 2021-09-08 Bharat Biotech Int Ltd Composiciones inmunogenicas de glicoconjugados multivalentes.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102935226A (zh) * 2012-11-16 2013-02-20 罗益（无锡）生物制药有限公司 伤寒甲型副伤寒结合疫苗及其制备方法
CN105744951A (zh) * 2013-08-24 2016-07-06 巴拉特生物技术国际有限公司 细菌疫苗及其制备方法
CN104383532A (zh) * 2014-12-02 2015-03-04 云南沃森生物技术股份有限公司 一种用乙肝表面抗原为载体蛋白的细菌多糖蛋白结合物疫苗及其制备方法
US20180185465A1 (en) * 2015-07-04 2018-07-05 Bharat Biotech International Limited Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides
US20190134177A1 (en) * 2016-04-25 2019-05-09 National Institute Of Immunology Conjugate for vaccination against typhoid comprising chemical conjugate of vi polysaccharide and flagellin, a process for producing the same and a composition comprising the conjugate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AAMIR ALI等: "Synthesis and immunogenicity evaluation of Salmonella enterica serovar Paratyphi A O-specific polysaccharide conjugated to diphtheria toxoid", 《HUMAN VACCINES & IMMUNOTHERAPEUTICS》, vol. 10, no. 6, 6 March 2014 (2014-03-06), pages 1494 - 1498, XP055795554, DOI: 10.4161/hv.28130 *

Also Published As

Publication number Publication date
US20230149524A1 (en) 2023-05-18
IL291006A (en) 2022-05-01
JP2024178271A (ja) 2024-12-24
AU2020343943A1 (en) 2022-03-24
PH12022550525A1 (en) 2023-03-20
CA3149972A1 (en) 2021-03-11
KR20240155975A (ko) 2024-10-29
GEAP202515919A (en) 2025-05-27
JOP20200214A1 (ar) 2021-03-03
PY2051122A (es) 2021-08-11
EP4249061A3 (en) 2023-11-15
EP4025246A2 (en) 2022-07-13
PE20221442A1 (es) 2022-09-21
CR20220132A (es) 2022-05-06
IL291006B2 (en) 2026-03-01
WO2021044436A3 (en) 2021-05-27
MX2022002693A (es) 2022-07-12
GB202204276D0 (en) 2022-05-11
JP7732974B2 (ja) 2025-09-02
GB2629746B (en) 2025-01-29
GB2603362A (en) 2022-08-03
IL291006B1 (en) 2025-11-01
GEP20257808B (en) 2025-10-27
US20250134980A1 (en) 2025-05-01
ZA202203368B (en) 2022-05-25
GB2629746A (en) 2024-11-06
WO2021044436A2 (en) 2021-03-11
BR112022003892A2 (pt) 2022-05-24
KR20220087437A (ko) 2022-06-24
GB2603362B (en) 2025-01-15
ECSP22031077A (es) 2022-05-31
AR119884A1 (es) 2022-01-19
JP2022546763A (ja) 2022-11-08
CO2022003789A2 (es) 2022-04-19
MA56283A1 (fr) 2023-01-31
EP4249061A2 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
JP7714690B2 (ja) コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
CN114887048B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
JP6884145B2 (ja) 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
HK1257816A1 (zh) 包含缀合的荚膜糖抗原的免疫原性组合物及其试剂盒和用途
US20250134980A1 (en) Immunogenic compositions against enteric diseases and methods for its preparation thereof
US20220387576A1 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
JPWO2018074296A1 (ja) 低分子化ＰＲＰを用いたＨｉｂコンジュゲートワクチンの製造方法
JP7804631B2 (ja) コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
EA051989B1 (ru) Иммуногенные композиции против кишечных заболеваний и способы их получения
OA20613A (en) Immunogenic compositions against enteric diseases and methods for its preparation thereof.
EA053072B1 (ru) Иммуногенные композиции против кишечных заболеваний и способы их получения
BR122024027321A2 (pt) Composições imunogênicas de vacina
TW202600584A (zh) 包含結合的莢膜醣抗原的免疫原性組合物及其用途
HK40074022A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20240086722A (ko) 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
HK40074440A (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
HK40074022B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
HK40023130B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
HK40023130A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
HK40021072B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
HK40021072A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination